Invasive fungal disease
Conditions
Interventions
Group of patients with invasive mycoses:Blood samples were collected at different time points for drug concentration monitoring.
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Aged over 65 years, with no restriction on gender; 2.Diagnosed with invasive aspergillosis and mucormycosis; 3.Receiving isavuconazole treatment (including loading dose and maintenance dose), with an anticipated treatment duration of = 48 hours; 4.Clinically stable and able to undergo blood sample collection; 5.Having consented to participate in the study and voluntarily signed the informed consent form.\
Exclusion criteria
Exclusion criteria: 1.Allergy to any component of isavuconazole; 2.Pregnant women, breastfeeding women, or patients planning to become pregnant in the near future; 3.Inability to collect an adequate blood sample due to the patient's condition or technical reasons; 4.Patients deemed unsuitable for participation in the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentration; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vital signs;Complete Blood Count;Serum Biochemistry;Coagulation Function;Electrocardiogram;Chest Computed Tomography; | — |
Countries
China
Contacts
Public ContactYun Cai
Chinese PLA General Hospital
Outcome results
None listed